Delcath Systems (NASDAQ:DCTH) Price Target Raised to $36.00

Delcath Systems (NASDAQ:DCTH) had its price objective raised by HC Wainwright from $32.00 to $36.00 in a research report released on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Delcath Systems’ Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at $0.13 EPS, Q2 2027 earnings at $0.11 EPS, Q3 2027 earnings at $0.22 EPS, FY2027 earnings at $0.33 EPS, FY2028 earnings at $0.68 EPS, FY2029 earnings at $1.08 EPS and FY2030 earnings at $1.61 EPS.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings cut Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. BTIG Research increased their target price on Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Zacks Research cut Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Delcath Systems has an average rating of “Moderate Buy” and an average price target of $29.33.

Delcath Systems Stock Performance

DCTH opened at $21.38 on Tuesday. The company has a fifty day moving average price of $15.80 and a two-hundred day moving average price of $12.65. Delcath Systems has a 52 week low of $8.12 and a 52 week high of $22.51. The firm has a market capitalization of $743.81 million, a PE ratio of 133.62 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Monday, November 9th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.26. The company had revenue of $35.10 million during the quarter, compared to analysts’ expectations of $25.99 million. Delcath Systems had a net margin of 6.05% and a return on equity of 5.56%. Equities analysts forecast that Delcath Systems will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds have recently bought and sold shares of DCTH. Integrated Wealth Concepts LLC acquired a new position in shares of Delcath Systems in the 2nd quarter valued at $48,000. IFP Advisors Inc acquired a new stake in Delcath Systems during the 2nd quarter worth $52,000. Royal Bank of Canada raised its stake in Delcath Systems by 14.8% during the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after buying an additional 2,364 shares during the period. Kopp Family Office LLC bought a new position in Delcath Systems during the third quarter worth about $450,000. Finally, Allspring Global Investments Holdings LLC bought a new position in Delcath Systems during the first quarter worth about $306,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Key Delcath Systems News

Here’s some of the latest news about DCTH:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $36 price target while lifting its FY2026 EPS estimate to $0.13 from a projected loss of $0.17 and its FY2027 estimate to $0.33 from $0.12. The higher forecasts imply improved expectations for profitability. Article: HC Wainwright earnings estimate revisions
• Positive Sentiment: A Zacks report says the analyst consensus price target suggests 27.7% upside and notes that upward earnings-estimate revisions could support the stock. It cautions, however, that price targets alone have limited predictive value. Article: Wall Street analysts see potential upside
• Neutral Sentiment: Delcath is scheduled to appear on “Health Uncensored with Dr. Drew” in a segment about liver-directed cancer treatment. The feature may raise awareness, but the announcement gives no indication of a direct financial impact. Article: Delcath to be featured on Health Uncensored

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.